CYP4F8 and osteosarcoma: In conclusion, this study identified statistically significant associations for a genetic variant in SULT1E1 with MTX plasma levels and three genetic variants in CYP2B6 and CYP4F8 with thrombocyte counts after HD-MTX infusion in osteosarcoma patients.